NDUFS1
ENSG00000023228
Target class
Enzyme
Chromosome
2
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- CI-75k
- Target name
- NDUFS1
- Gene name
- NADH:ubiquinone oxidoreductase core subunit S1
- Gene symbol
- NDUFS1
- Protein name
- NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial (EC 7.1.1.2) (Complex I-75kD) (CI-75kD)
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase core subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 50.58
- Tissue specificity (Gini)
- 0.198
- Tissue specificity (tau)
- 0.663
- KEGG gene identifiers
- hsa:4719
- R-HSA-611105
- R-HSA-6799198
- R-HSA-9837999
- End position
- 206159522
- Start position
- 206114817
- Chromosome
- 2
- Strand
- Reverse
- Mitochondrion inner membrane
- Peripheral membrane protein
- Matrix side .
- Mitochondria
- PubMed 12611891
- PubMed 30879903
- Tissue specificity (tau)
- 0.663127
- Expression inequality (Gini)
- 0.197864
Expression in transcripts per million
- Muscle - Skeletal
- 50.58
- Heart - Left Ventricle
- 42.39
- Adrenal Gland
- 32.12
- Heart - Atrial Appendage
- 31.04
- Cells - EBV-transformed lymphocytes
- 24.82
Expression in transcripts per million
- Muscle - Skeletal50.58
- Heart - Left Ventricle42.39
- Adrenal Gland32.12
- Heart - Atrial Appendage31.04
- Cells - EBV-transformed lymphocytes24.82
- Brain - Cerebellar Hemisphere24.72
- Cells - Cultured fibroblasts23.81
- Brain - Frontal Cortex (BA9)22.58
- Brain - Cerebellum20.68
- Colon - Transverse20.53
- Artery - Tibial20.51
- Esophagus - Muscularis20.44
- Colon - Sigmoid19.63
- Esophagus - Gastroesophageal Junction19.52
- Esophagus - Mucosa18.54
- Cervix - Ectocervix18.18
- Stomach17.79
- Nerve - Tibial17.37
- Bladder17.29
- Brain - Cortex17.15
- Vagina17.06
- Uterus16.89
- Artery - Coronary16.73
- Adipose - Subcutaneous16.55
- Artery - Aorta16.46
And 29 more, listed on the interactive page.
- GO:0006120
- GO:0032981
- GO:0045333
- GO:0005739
- GO:0005743
- GO:0005758
- GO:0005759
- GO:0045271
- GO:0005515
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor